相关临床试验
565
50 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1896
进行中（未招募）
31
5.5%
已完成
348
61.6%
Enrolling By Invitation
4
0.7%
尚未招募
15
2.6%
招募中
66
11.7%
暂停
1
0.2%
终止
63
11.2%
Unknown
4
0.7%
撤回
33
5.8%
暂无批准数据
- A multicenter retrospective case series found that 87% of patients receiving high-dose oral vitamin D reported symptom relief from chemotherapy- or radiation-induced skin toxicities within 10 days. - Median time to improvement was 5 days overall and just 3 days among hospitalized patients, with no treatment-related adverse events or meaningful changes in serum calcium. - Nearly three-quarters (73%) of patients were able to continue anticancer therapy without interruption after vitamin D intervention. - The findings, published in JAMA Dermatology, support further prospective controlled studies to confirm efficacy and establish optimal dosing.
- A new study in BMJ Mental Health uses AI-generated simulations to estimate the risk of harm when patients with mental health conditions use AI chatbots, finding risk varies by roughly four orders of magnitude depending on the model and patient context. - Researchers tested 14 open-source AI models on three safety tasks—recognizing suicidal ideation, therapy requests, and therapy-like conversation drift—with two psychiatrists validating all synthetic exchanges. - The tools were weakest at detecting subtle suicidal ideation, including ambivalent or conditional language, mirroring the areas that demand the most clinical skill. - A companion clinical framework advises therapists to assess dose, content, function, substitution, and the specific chatbot when patients disclose AI use, addressing a teachable gap in clinician preparedness.
- A Harvard-Stanford study published in Science found that OpenAI's o1 model matched or exceeded experienced physicians on diagnostic tasks using real emergency-room cases. - Researchers caution that the study does not prove AI is ready for standard medical practice, while unvetted AI tools are already proliferating across U.S. healthcare. - Diagnostic errors kill or permanently disable nearly 800,000 Americans annually, and poorly controlled chronic diseases contribute to 50% of heart attacks, strokes, and kidney failures. - Experts call for structured evaluation of medical AI, with proposals ranging from FDA authorization pathways to licensing-exam and residency-style oversight for chatbots.
- Google's AMIE AI system safely conducted pre-visit medical interviews with 100 urgent care patients, with no safety incidents requiring physician intervention during supervised interactions. - The AI demonstrated diagnostic capabilities comparable to human physicians, generating appropriate differential diagnoses in blinded evaluations with no significant quality differences. - While AMIE matched clinicians in diagnostic accuracy and safety, human doctors significantly outperformed the AI in creating practical and cost-effective management plans. - Patient attitudes toward medical AI improved significantly after interacting with AMIE, suggesting potential for enhanced patient acceptance of AI-assisted healthcare.
- The FDA approved Cosentyx (secukinumab) for treating pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa, making it the first IL-17A inhibitor approved for this population. - More than half of hidradenitis suppurativa patients develop symptoms during adolescence, highlighting the critical importance of early intervention with biologics to reduce long-term disease burden. - The approval is supported by well-controlled adult studies and pharmacokinetic modeling, with weight-based dosing predicted to provide similar drug exposure in pediatric patients as in adults. - This marks the fourth pediatric indication for Cosentyx, addressing a significant treatment gap for younger patients with limited therapeutic options in this challenging condition.
- Biomerica's real-world study of 69 IBS patients demonstrated that 59.4% achieved clinically meaningful abdominal pain reduction and 68.1% experienced significant bloating relief using FDA-recognized responder endpoints. - The Centers for Medicare & Medicaid Services established a $300 national Medicare payment rate for the inFoods IBS test, effective January 1, 2026, providing reimbursement clarity for the diagnostic. - Real-world results closely mirror the company's peer-reviewed randomized controlled trial published in Gastroenterology, which showed 59.6% pain response rates across five major academic centers. - The personalized diagnostic approach targets an estimated 30-45 million IBS patients in the United States through food sensitivity testing and targeted dietary interventions.
- The everolimus-eluting Esprit BTK resorbable scaffold demonstrated a 33% relative improvement in the composite primary efficacy endpoint compared to balloon angioplasty at 3 years (59.5% vs 44.8%, P = 0.0025). - Binary restenosis rates were significantly lower with the scaffold versus angioplasty (38% vs 49%, P = 0.018), with clinically driven target lesion revascularization trending lower (10.2% vs 18.4%, P = 0.052). - The scaffold maintained comparable safety outcomes to angioplasty with no evidence of inflammatory processes or scaffold thrombosis, even as the device structure completely dissolved by 3 years. - Subgroup analyses revealed greater benefit in patients with Rutherford-Becker class 4 disease and those not requiring inflow lesion treatment, suggesting potential for personalized treatment strategies.
- Bondia™, a first-in-class synbiotic medical food, reduced bone loss in the femoral neck by 85% in postmenopausal women with osteopenia compared to placebo in a landmark clinical trial. - The breakthrough study published in Osteoporosis International represents the largest-ever probiotic medical food trial for bone health, following 286 postmenopausal women. - New mechanistic research published in the Journal for Functional Foods demonstrates how Bondia™ strengthens gut barrier integrity, reduces inflammation, and directly inhibits bone-resorbing osteoclast activity. - The National Institute on Aging is funding an 18-month clinical trial (STARS) involving 220 women aged 60 and above to further validate Bondia™'s efficacy in managing bone loss.
- CND Life Sciences received FDA Breakthrough Device Designation for its Syn-One Test, a skin biopsy diagnostic tool that demonstrates 95.5% sensitivity in detecting abnormal synuclein in patients with synuclein-associated diseases. - The company was awarded a $3 million NIH grant to conduct a three-year multicenter study investigating whether the Syn-One Test can predict Parkinson's disease risk in essential tremor patients. - A Yale University study showed the Syn-One Test changed diagnosis in 52% of cases and medical management in 60% of 149 evaluable patients, demonstrating significant clinical utility. - The diagnostic test uses proprietary immunofluorescence techniques to detect phosphorylated alpha-synuclein in cutaneous nerves through a simple in-office skin biopsy procedure.
- Brainlab has received FDA 510(k) clearance and launched its Spine Mixed Reality Navigation system in the United States, combining optical navigation with advanced mixed reality for pedicle screw placement. - The system projects real-time visualization directly in the surgeon's field of view, eliminating the need to look between the operative site and navigation screen during minimally invasive spine surgery. - Clinical testing demonstrated surgeons could efficiently place 100 screws over two days while maintaining constant focus on anatomy, with the headset remaining comfortable during seven-hour procedures. - The technology is already being used by European surgeons and represents a significant advancement in spinal surgery precision and workflow optimization.
